Related Experiment Video
Updated: Dec 21, 2025

An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection
Published on: October 6, 2015
What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control?
Floriano Amimo1,2, Ben Lambert3, Anthony Magit4
11Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Insights
The COVID-19 pandemic threatens to worsen existing health crises in Africa, including HIV, TB, and malaria. Current control measures overlook the region's unique social and economic challenges, potentially hindering access to essential treatments for vulnerable populations.
Area of Science:
- Global Health
- Epidemiology
- Public Health Policy
Background:
- Africa faces significant health burdens from HIV, tuberculosis (TB), and malaria.
- COVID-19 poses a risk of exacerbating these existing epidemics due to vulnerable health and economic systems.
- Existing control measures for COVID-19 may not adequately address Africa's specific epidemiological and socioeconomic context.
Purpose of the Study:
- To examine the potential implications of COVID-19 on the control of HIV, TB, and malaria in Africa.
- To analyze how current COVID-19 control measures interact with Africa's unique social, economic, and epidemiological realities.
- To identify potential challenges in accessing essential health services for vulnerable populations during the COVID-19 pandemic.
Main Methods:
- Literature review of current evidence on HIV, TB, and malaria disease burden in Africa.
- Analysis of COVID-19 epidemic dynamics and control measures within the African context.
- Assessment of the socioeconomic impact of COVID-19 control strategies on vulnerable populations.
Main Results:
- COVID-19 control measures may neglect crucial context-specific factors in Africa.
- Similarities in symptoms between COVID-19, TB, and malaria, coupled with mistrust, may deter care-seeking.
- Economic and logistical challenges associated with COVID-19 responses could impede access to vital treatments for HIV, TB, and malaria, particularly for pregnant women and children.
Conclusions:
- COVID-19 responses in Africa must integrate specific epidemiological, social, and economic considerations.
- Failure to adapt measures could lead to compromised drug efficacy, increased health inequalities, and worsened outcomes for major diseases.
- Protecting vulnerable and underserved populations should be a central component of country-level COVID-19 strategies.
Abstract:
Despite its current relatively low global share of cases and deaths in Africa compared to other regions, coronavirus disease 2019 (COVID-19) has the potential to trigger other larger crises in the region. This is due to the vulnerability of health and economic systems, coupled with the high burden of human immunodeficiency virus (HIV), tuberculosis (TB), and malaria. Here we examine the potential implications of COVID-19 on the control of these major epidemic diseases in Africa. We use current evidence on disease burden of HIV, TB, and malaria, and epidemic dynamics of COVID-19 in Africa, retrieved from the literature. Our analysis shows that the current measures to control COVID-19 neglect important and complex context-specific epidemiological, social, and economic realities in Africa. There is a similarity of clinical features of TB and malaria, with those used to track COVID-19 cases. This coupled with institutional mistrust and misinformation might result in many patients with clinical features similar to those of COVID-19 being hesitant to voluntarily seek care in a formal health facility. Furthermore, most people in productive age in Africa work in the informal sector, and most of those in the formal sector are underemployed. With the current measures to control COVID-19, these populations might face unprecedented difficulties to access essential services, mainly due to reduced ability of patients to support direct and indirect medical costs, and unavailability of transportation means to reach health facilities. Therefore, if not accompanied with appropriate economic and epidemiological considerations, we anticipate that these measures might result in unprecedented difficulties among vulnerable segments of society to access essential services, including antiretroviral and prophylactic drugs among people living with HIV and Acquired Immune Deficiency Syndrome, anti-tuberculosis drugs, and curative and preventive treatments for malaria among pregnant women and children. This might increase the propensity of patients taking substandard doses and/or medicines, which has the potential to compromise drug efficacy, and worsen health inequalities in the region. COVID-19 responses at country level should include measures to protect vulnerable and under-served segments of society.
More Related Videos
09:02An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
Published on: February 17, 2014
07:39An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells
Published on: August 15, 2012
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Sexually Transmitted Infections
Retrovirus Life Cycles
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories: